$100 million more from Gates

The linkurl:Bill & Melinda Gates Foundation;http://www.the-scientist.com/article/display/25259/ has established a new five-year $100 million fast-track grant program for global health research. Each project will receive $100,000, with the option of additional funding if merited. The program, which will adopt a fast-track review, is for scientists with "creative concepts" to fight global health scourges affecting developing countries, such as vaccines, drugs, and diagnostics. One of the

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The linkurl:Bill & Melinda Gates Foundation;http://www.the-scientist.com/article/display/25259/ has established a new five-year $100 million fast-track grant program for global health research. Each project will receive $100,000, with the option of additional funding if merited. The program, which will adopt a fast-track review, is for scientists with "creative concepts" to fight global health scourges affecting developing countries, such as vaccines, drugs, and diagnostics. One of the goals of the initiative is to "support paradigm-changing ideas that have never before been tested, and that might not stand up to traditional peer review." To expedite the review process, funding proposals should be "relatively short" and can avoid preliminary data, they will be reviewed within three months, and grants can be awarded several times per year. The first call for proposals will appear in early 2008, on the linkurl:Grand Challenges in Global Health;http://www.gcgh.org/channels/gcgh Web site. James Aiken, President and Chief Executive Officer, Keystone Symposia on Molecular & Cellular Biology, took it upon himself to send an Email about the program to Keystone participants: "Keystone Symposia never shares, and only rarely uses our mailing lists for anything other than Keystone Symposia business. In this case, however, I felt that this new opportunity for grants was something that most of our participants would like to know about."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies